Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: ZNTL stock price vs MET: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MET's multiple
Needs MET P/S.
Implied fair value · at ZNTL's multiple
Needs ZNTL P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ZNTL FY 2024 (ended Dec 31, 2024) · MET FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Zentalis Pharmaceuticals, Inc. · implied price per share
Bear
-$2.26
Base
-$2.66
Bull
-$3.06
MetLife, Inc. · implied price per share
Bear
$64.14
Base
$75.46
Bull
$86.77
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.29x
0.52x
Net debt / EBITDA
Leverage against operating earnings
-0.19x
-1.41x
Cash and equivalents
Liquid reserves on the balance sheet
$36.00M
$25.63B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Arcus Biosciences, Inc.
ZNTL vs RCUS
Repare Therapeutics Inc.
ZNTL vs RPTX
IDEAYA Biosciences, Inc.
ZNTL vs IDYA
Mersana Therapeutics, Inc.
ZNTL vs MRSN
EXELIXIS, INC.
ZNTL vs EXEL
AFLAC INC
ZNTL vs AFL
American International Group, Inc.
ZNTL vs AIG
LINCOLN NATIONAL CORP
ZNTL vs LNC
HARTFORD FINANCIAL SERVICES GROUP, INC.
ZNTL vs HIG
$61.78M
$14.82B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Price unavailable
